MedTrace Logo

Moxidectin for LF, Cote d'Ivoire (DOLF)

NCT04410406 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).

Conditions

  • Lymphatic Filariasis

Interventions

DRUG

Ivermectin

Ivermectin (IVM) 200 µg/kg

DRUG

Diethylcarbamazine

Diethylcarbamazine (DEC) 6mg/kg

DRUG

Albendazole

Albendazole (ABZ) 400 mg

DRUG

Moxidectin

Moxidectin (Mox) 8 mg

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • Centre Suisse de Recherches Scientifiques en Cote d'Ivoire

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Philip Budge, MD, PhD · Washington University School of Medicine

  • Catherine Bjerum, MD, MPH · Case Western Reserve University

  • Toki Pascal Gabo, MD · Regional Hospital of Agboville, Southern Cote d'Ivoire

  • Benjamin Koudou, PhD · Regional Hospital of Agboville, Southern Cote d'Ivoire

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-20
Primary Completion
2024-10-01
Completion
2024-10-01
FDA Drug
Yes

Countries

  • Côte d’Ivoire

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04410406 on ClinicalTrials.gov